Tag Archives: brodalumab

February, 2017

  • 17 February

    FDA Approves Valeant’s Siliq for Treatment of Psoriasis

    LAVAL, Quebec , Feb. 16, 2017 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (“Valeant” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for SILIQ™ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the …

July, 2016

  • 20 July

    FDA Panel Recommends Approval of Valeant’s Psoriasis Drug

    LAVAL, Quebec, July 19, 2016 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) has voted by a margin of 18 to 0 for the approval of brodalumab injection, 210 …

  • 1 July

    AstraZeneca Licenses Two Dermatology Drugs to Leo Pharma

    AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic disease and Oncology. The agreements include two of AstraZeneca’s potential new medicines for dermatitis and psoriasis, allowing the Company to further simplify and sharpen …

May, 2015

  • 26 May

    Amgen Terminates its Partnership with AstraZeneca on Psoriasis Drug

    Amgen is terminating its partnership with AstraZeneca surrounding the psoriasis drug brodalumab in late-stage development. The company announced that it has commenced termination of its participation in the co-development and commercialization of brodalumab, an investigational IL-17 inhibitor, with AstraZeneca. The drug is in development for patients with moderate-to-severe plaque psoriasis, …